Table 1.
Selected trials of daratumumab and isatuximab in RRMM.
| Study Name | Phase | Setting | Treatment | Number of Patients | ORR (%) | CR (%) | MRD Neg (%) | NCT Number | References |
|---|---|---|---|---|---|---|---|---|---|
| ALCYONE (MMY3007) | 3 | NTE NDMM | Dara-VMP vs. VMP | 706 | 90.9 vs. 73.9 | 42.6 vs. 24.4 | 22.3 vs. 6.2 | NCT03158688 | [36,37] |
| MAIA (MMY3008) | 3 | NTE NDMM | Dara-Rd vs. Rd | 737 | 92.9 vs. 81.3 | 47.6 vs. 24.9 | 24.2 vs. 7.3 | NTC02252172 | [38,39] |
| CASSIOPEIA (MMY3006) |
3 | TE NDMM | Dara-VTD vs. VTD | 1085 | 92.6 vs. 89.9 | 39 vs. 26 | 64 vs. 44 | NTC02541383 | [35,40] |
| POLLUX (MMY3003) | 3 | RRMM | Dara-Rd vs. Rd | 569 | 92.9 vs. 76.4 | 43.1 vs. 19.2 | 22.4 vs. 4.6 | NCT02076009 | [41] |
| CASTOR (MMY3004) | 3 | RRMM | Dara-Vd vs. Vd | 500 | 85 vs. 63 92 vs. 74 (1 prior line treatment) |
30 vs. 10 43 vs. 15 |
14 vs. 2 20 vs. 3 |
NCT02136134 | [42] |
| CANDOR | 3 | RRMM | Dara-Kd vs. Kd | 466 | 84.3 vs. 74.7 | 29 vs. 10 | 14 vs. 3 | NCT03158688 | [35,43] |
| IKEMA | 3 | RRMM | Isa-Kd vs. Kd | 302 | 87 vs. 83 | 40 vs. 28 | 30 vs. 13 | NCT03275285 | [35,45] |
| ICARIA-MM | 3 | RRMM | Isa-Pd vs. Pd | 307 | 60 vs. 35 | 5 vs. 2 | 5 vs. 0 | NCT02990338 | [44,46] |
NTE = non transplant eligible, TE = transplant eligible, RRMM = relapsed/refractory multiple myeloma, ORR = overall response rate, CR = complete response, and MRD = minimal residual disease.